Skip to main content
OpenTrials
Completed

NCT Number: NCT02275650

The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter

The investigators investigated the ability of narrowband ultraviolet B (nbUVB) treatment in the maintenance of vitamin D levels achieved during the summer in Finland. The investigators randomized 37 subjects into groups of 17 and 18 subjects. The other group received 2 standard erythema doses (SED) nbUVB exposure every other week until week 24, and serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30. The control group was not illuminated and serum samples were analyzed correspondingly. Punch biopsies were taken at the onset and at week 14 for CYP27A1 and CYP27B1 enzyme expression level analyses.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vitamin D Deficiency Avitaminosis Congenital, Hereditary, and Neonatal Diseases and Abnormalities Deficiency Diseases Genetic Diseases, Inborn Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Malnutrition Metabolic Diseases Metabolism, Inborn Errors Nutrition Disorders Nutritional and Metabolic Diseases Xanthomatosis Xanthomatosis, Cerebrotendinous

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Päijät-Häme Central Hospital, Lahdenkylä, Pirkanmaa, Finland

Loading trial locations.

About this study

The investigators investigated the ability of narrowband ultraviolet B (nbUVB) treatment in the maintenance of vitamin D levels achieved during the summer in Finland. The investigators randomized 37 subjects into groups of 17 and 18 subjects. The other group received 2 standard erythema doses (SED) nbUVB exposure every other week until week 24, and serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30. The control group was not illuminated and serum samples were analyzed correspondingly. 6mm punch biopsies were taken at the onset and at week 14 for CYP27A1 and CYP27B1 enzyme expression level analyses.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age over 18
  • Fitzpacker's skin type II-IV

Exclusion criteria

  • age under 18
  • diseases that inhibit vitamin D metabolism or absorption
  • Fitzpacker's skin type I
  • history of skin cancer
  • vitamin D substitution 1 month before baseline or during study
  • sun holidays 1 month before baseline or during study

Treatment and study plan

nbUVB

Radiation

2 SED nbUVB exposure will be given every other week

Primary outcomes

  1. 25(OH)D level

    Time frame: up to 30 weeks

    Serum 25(OH)D levels were measured at the onset and at weeks 6, 14, 20, 26 and 30.

Secondary outcomes

  1. CYP27A1 and CYP27B1 enzyme expression levels

    Time frame: up to 14 weeks

    CYP27A1 and CYP27B1 enzyme expression levels will be analysed from 6mm punch biopsies at the onset and at week 14.

Sponsors and collaborators

Lead sponsor

Joint Authority for Päijät-Häme Social and Health Care

Other

Collaborators

  • Tampere University Hospital

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Oct 27, 2014
Registry last updated
Oct 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.